Monopar Therapeutics (MNPR) Retained Earnings (2016 - 2020)
Monopar Therapeutics (MNPR) has disclosed Retained Earnings for 4 consecutive years, with -$10044.0 as the latest value for Q3 2020.
- Quarterly Retained Earnings rose 99.96% to -$10044.0 in Q3 2020 from the year-ago period, while the trailing twelve-month figure was -$10044.0 through Sep 2020, up 99.96% year-over-year, with the annual reading at -$25.9 million for FY2019, 1080058.01% down from the prior year.
- Retained Earnings hit -$10044.0 in Q3 2020 for Monopar Therapeutics, up from -$28.4 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$1579.0 in Q2 2018 to a low of -$28.4 million in Q2 2020.
- Historically, Retained Earnings has averaged -$8.3 million across 4 years, with a median of -$12527.5 in 2020.
- Biggest YoY gain for Retained Earnings was 99.98% in 2019; the steepest drop was 1080058.01% in 2019.
- Year by year, Retained Earnings stood at -$1.9 million in 2016, then soared by 99.87% to -$2396.0 in 2018, then plummeted by 1080058.01% to -$25.9 million in 2019, then skyrocketed by 99.96% to -$10044.0 in 2020.
- Business Quant data shows Retained Earnings for MNPR at -$10044.0 in Q3 2020, -$28.4 million in Q2 2020, and -$15011.0 in Q1 2020.